文献速递血液透析通路

他汀类药物对糖尿病患者前臂动静脉瘘血栓形成的保护作用

Statins Protect against Thrombosis of Cannulated Radiocephalic Fistulas in Diabetic Patients.
PubMed 文献 · Ann Vasc Surg · 2021-02-04

回顾性分析15年间122例糖尿病男性患者的123例桡动脉-头静脉动静脉瘘(RCAVF)建立,比较他汀组与非他汀组的结局。他汀组穿刺后RCAVF血栓发生率显著更低(P=0.0005),无血栓生存率更高(P=0.0003),他汀使用是唯一与无血栓相关的显著因素(P=0.05)。

要点

  • 糖尿病患者建立RCAVF时使用他汀与穿刺后血栓风险降低独立相关。
  • 他汀组与非他汀组的穿刺成功率、功能通畅时间和每次通路干预次数无差异。
  • 结果支持进一步研究他汀在血液透析通路中的作用。

核心结论

  • 他汀对糖尿病初次RCAVF患者穿刺后血栓形成有保护作用。
  • 他汀组与非他汀组在穿刺成功率、功能通畅时间及每次通路干预次数上相似。

研究设计与样本

  • 回顾性队列研究,查询退伍军人事务医院透析通路数据库15年期间数据。
  • 共纳入122例糖尿病男性患者的123例RCAVF,92例使用他汀,31例未使用。

主要发现

  • 他汀组穿刺后RCAVF血栓发生率显著低于非他汀组(P=0.0005)。
  • Kaplan-Meier分析显示他汀组无血栓通路生存率显著更高(log-rank P=0.0003)。
  • 单因素逐步logistic回归显示他汀使用是唯一与无血栓相关的显著因素(P=0.05)。

临床怎么用

  • 糖尿病男性患者建立RCAVF时可考虑他汀治疗以降低穿刺后血栓风险。
  • 他汀不影响穿刺成功率、功能通畅时间或干预次数。

局限性

  • 回顾性设计,仅纳入糖尿病男性退伍军人,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiocephalic arteriovenous fistula (RCAVF) creation is the preferred first line hemodialysis access procedure. Analysis of diabetic rat arteriovenous fistula model indicates improved vascular function with HMG-CoA-Reductase Inhibitor (statin) use. We predict similar outcomes in diabetic patients undergoing primary RCAVF placement. METHODS: A Veterans Administration Hospital dialysis access database over a 15-year period was queried identifying all RCAVF placements in diabetic patients. Patients were stratified into statin medication usage or not at RCAVF creation. Outcomes examined include rate of successful cannulation, functional patency duration, interventions per access, and rates of access thrombosis. Thrombosis-free survival of cannulated RCAVFs were compared using Kaplan-Meier method with log-rank analysis followed by univariate, stepwise logistic regression and ROC curve analysis. RESULTS: Total number of 123 RCAVF cases were performed in 122 diabetic male patients. At the time of RCAVF placement, 92 cases were performed on patients that were taking statin medication and 31 cases were performed on patients that were not taking statin medication. There was no difference in terms of rate of successful cannulation, functional patency duration, and number of interventions per access between the statin and non-statin groups. However, rate of RCAVF thrombosis once accessed was significantly lower in the statin group compared to the non-statin group (P = 0.0005). Kaplan-Meier survival curve for each group were compared using log-rank test to reveal that diabetic patients who were on statin therapy at the time of operation had significantly higher access survival over time against thrombosis once it was cannulated for dialysis treatment compared to those who were not on statin therapy (P = 0.0003). Univariate, stepwise logistic regression model indicated statin use as the only significant factor associated with lack of thrombosis (P = 0.05). CONCLUSIONS: Statins appear to have protective effects against RCAVF thrombosis as predicted in animal models for diabetic patients undergoing primary RCAVF placements. There were similar functional outcomes in terms of rate of successful cannulation, functional patency duration, and number of interventions per access. These data should encourage further investigation of statins and their role in hemodialysis access.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Suh D, Amendola MF, Reeves M, et al. Statins Protect against Thrombosis of Cannulated Radiocephalic Fistulas in Diabetic Patients. Ann Vasc Surg. 2021. PMID: 33549796. doi:10.1016/j.avsg.2021.01.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。